This present study is the first to report on the therapeutic efficacy and potential benefit of p53 activation with concurrent BCL-xL/BCL-2 inhibition against an extensive range of preclinical models of high-risk and relapsed ALL, demonstrating the broad applicability of the combination in both B- and T-ALL. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.